The largest database of trusted experimental protocols

Dharmafect 2 transfection reagent

Manufactured by GE Healthcare
Sourced in United Kingdom

DharmaFECT-2 is a lipid-based transfection reagent designed for efficient delivery of small interfering RNA (siRNA) and other nucleic acids into a variety of cell types. The reagent facilitates the uptake of nucleic acid molecules into the target cells, enabling gene silencing or other gene expression studies.

Automatically generated - may contain errors

3 protocols using dharmafect 2 transfection reagent

1

Transfection and Viability Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
24 hours before transfection, cells were seeded in media containing 10% FBS without antibiotics. Cells were then transfected with control siRNA (Cell Signaling), PRMT-1 siRNA (Dharmacon), or p120-catenin siRNA (Santa Cruz Biotechnology) using Dharmafect-2 transfection reagent, (GE Life Sciences) per manufacturer’s protocol. Cell lysates were collected for immunoblotting after 24 and 48 hours. For MTT cell viability assays, the transfection media was removed after 24 hours followed by addition of drug media.
+ Open protocol
+ Expand
2

siRNA Knockdown of Smad2 and Smad3

Check if the same lab product or an alternative is used in the 5 most similar protocols
For siRNA knockdown experiments, 1.0 × 105 cells/well were seeded into 6-well plates and were transfected with 100nM of ON-TARGETplus SMARTpool siRNAs (GE Healthcare, Little Chalfont, UK) specific for Smad2, Smad3, or a non-targeting control using 4 μL DharmaFECT 2 transfection reagent (GE Healthcare) per transfection according to the manufacturer's instructions. Cells were incubated overnight, and then treated with TGF-β1 for 3 d before use.
+ Open protocol
+ Expand
3

siRNA Analysis of MR and AhR

Check if the same lab product or an alternative is used in the 5 most similar protocols
Small interfering RNA (siRNA) analysis was carried out as previously described with slight modification. 5, 6 MR and AhR siRNA were the SMARTpool:ON-TARGETplus siRNA from GE Healthcare (Little Chalfont, United Kingdom). The control siRNA was the ON-TARGETplus Nontargeting control from GE Healthcare. Monocytes were transfected on day 0 with 50 nmol/L siRNA by using the DharmaFECT 2 Transfection Reagent (GE Healthcare). Inhibition was assessed at day 6.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!